Follicular lymphoma is a form of non-Hodgkin lymphoma characterized by a proliferation of B cells whose nodular structure of follicular architecture is preserved.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Documentation on follicular lymphoma is limited due to its relatively low prevalence, which restricts the number of systematic clinical studies. Additionally, the complexity of lymphoma types and the absence of a clearly defined genetic basis contribute to the challenges in understanding this condition fully. While this can be frustrating, ongoing research aims to improve our understanding and treatment options.
To navigate follicular lymphoma effectively, seek out a hematologist or oncologist with expertise in lymphoma management. Consider participating in clinical trials, which can provide access to cutting-edge therapies. You can also explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support. While no specific patient organizations are identified, connecting with clinical trial networks may offer valuable insights and community support.
There are currently 430 active clinical trials exploring various aspects of follicular lymphoma. Notable FDA-approved treatments include Kymriah and Yescarta, among others. Additionally, several orphan drugs are in development, such as 177Lu-tetraxetan-tetulomab. For more information on active trials, you can visit ClinicalTrials.gov at [this link](https://clinicaltrials.gov/search?cond=follicular%20lymphoma). This research landscape offers hope for better management and treatment of the condition.
Actionable guidance for navigating care for follicular lymphoma
To navigate follicular lymphoma effectively, seek out a hematologist or oncologist with expertise in lymphoma management. Consider participating in clinical trials, which can provide access to cutting-edge therapies. You can also explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for additional support. While no specific patient organizations are identified, connecting with clinical trial networks may offer valuable insights and community support.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning follicular lymphoma
Updated Feb 5, 2026
New immunotherapy combinations for relapsed or refractory follicular lymphoma show promising efficacy in recent phase III trials. The addition of tafasitamab or epcoritamab to lenalidomide–rituximab (R2) offers potential new treatment options for patients.